SB 204741

C₁₄H₁₄N₄OS

286.35

MFCD00923644

24278321

NA.77

SB 204741 has been used as a 5-hydroxytryptamine receptor 2B (Htr2B) antagonist:

• to inhibit Htr2b signaling to test its effect on hepatic stellate cell (HSC) activation in three-month-old adult zebrafish
• to test its effect on the inhibition of fluoxetine effects in depressive-like behavioral studies in mice
• to test its effect in reducing scratching behavior evoked by sertraline in mice

SB 204741 reduces the synaptic facilitation induced by the low dose of buprenorphine in spinal C-fiber synapses.
5-HT_2B serotonin receptor antagonist.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sold for research purposes under agreement from Glaxo­Smith­Kline

100

>98% (HPLC)

solid

off-white to tan

DMSO: soluble >20 mg/mL

GlaxoSmithKline

2-8℃

Cc1cc(NC(=O)Nc2ccc3n(C)ccc3c2)sn1

1S/C14H14N4OS/c1-9-7-13(20-17-9)16-14(19)15-11-3-4-12-10(8-11)5-6-18(12)2/h3-8H,1-2H3,(H2,15,16,19)

USFUFHFQWXDVMH-UHFFFAOYSA-N

human ... DRD2(1813), DRD3(1814), DRD5(1816), HTR1E(3354), HTR2A(3356), HTR2B(3357), HTR2C(3358)
rat ... Adra1a(29412), Gabra2(29706), Htr1a(24473), Htr2b(29581), Htr3a(79246)

10, 50 mg in glass bottle

GHS07

Warning

H315 - H319 - H335

P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Respiratory system

11 - Combustible Solids

WGK 3

dust mask type N95 (US), Eyeshields, Gloves